middle.news
Island Pharmaceuticals Partners with Texas Biomed to Advance Galidesivir Dose Optimisation
9:46am on Monday 13th of July, 2026 AEST
•
Pharmaceuticals
Read Story
Island Pharmaceuticals Partners with Texas Biomed to Advance Galidesivir Dose Optimisation
9:46am on Monday 13th of July, 2026 AEST
Key Points
Texas Biomed to evaluate Galidesivir at symptom onset in 12 primates
Study uses FDA-preferred Angola strain for regulatory alignment
Complements USAMRIID’s early treatment dose optimisation
Secures additional animal cohorts for operational flexibility
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Island Pharmaceuticals (ASX:ILA)
OPEN ARTICLE